Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 241,818 shares of the medical research company’s stock after acquiring an additional 2,426 shares during the period. Asset Management One Co. Ltd.’s holdings in Edwards Lifesciences were worth $18,294,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Alpha Financial Partners LLC acquired a new position in Edwards Lifesciences during the third quarter worth about $693,000. Trust Co. of Vermont lifted its stake in Edwards Lifesciences by 36.1% in the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after purchasing an additional 801 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Edwards Lifesciences by 10.6% during the 3rd quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company’s stock worth $992,000 after purchasing an additional 1,437 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $273,000. Finally, Net Worth Advisory Group acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $437,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.3 %

Shares of NYSE EW opened at $76.23 on Friday. The firm has a market cap of $44.96 billion, a P/E ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm’s 50 day moving average price is $72.67 and its 200 day moving average price is $69.50.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,489 shares of company stock valued at $2,002,829. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several analyst reports. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Evercore ISI lowered their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.